What Is ATIC? A New Australasian Forum on Type 1 Diabetes Immunotherapy

The Australasian Type 1 Diabetes Immunotherapy Collaborative held its first town hall to discuss immunotherapy research and clinical trials. Here's what you need to know about this new community initiative.

Community video — lay discussion, not peer-reviewed research

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cureresearchclinical trial

Key takeaways

ATIC is a collaborative forum focused on immunotherapy approaches to Type 1 diabetes in Australia and the broader Australasian region
The organization held its inaugural town hall event to connect researchers, clinicians, and community members
Town hall sessions are recorded and made available to the public, with Q&A documents provided for questions not addressed during live discussion
This is a community-led initiative rather than a peer-reviewed research study

Introducing ATIC

The Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC) held its inaugural town hall forum on February 22, 2023, bringing together researchers, clinicians, and community members interested in immunotherapy approaches to Type 1 diabetes. The event was designed as an open discussion platform rather than a formal research presentation.

During the town hall, organizers provided an overview of ATIC's mission, shared information about immunotherapy as a treatment approach, and discussed current clinical trials relevant to the Type 1 diabetes community in Australia and nearby regions.

How the Town Hall Works

The event featured a panel of experts who fielded questions from attendees through a moderated Q&A format. Participants were invited to submit questions via a dedicated question-and-answer system, allowing for organized discussion of topics most relevant to the community.

Sessions were recorded and made available to the public on ATIC's website within one week of the event. For questions that could not be addressed during the live discussion due to time constraints, organizers compiled written responses into a comprehensive Q&A document shared with all attendees.

What This Means for the Community

ATIC's town hall format offers an accessible way for people affected by Type 1 diabetes to learn about immunotherapy research developments and connect with experts in the field. By recording sessions and publishing Q&A responses, the collaborative makes information available beyond those who could attend live.

This community-focused approach reflects growing recognition that research discussions should be transparent and open to patients, parents, and caregivers—not just medical professionals.

Evidence label

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.